Clinical Trials & Data

Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Iovance Biotherapeutics Inc. is frequently cited as one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot clinical trial evaluating its lifileucel TIL (Tumor-Infiltrating Lymphocytes) cell therapy in patients with advanced soft tissue sarcomas.

The study strategically focused on individuals with metastatic or unresectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) who had unfortunately failed at least one prior systemic treatment.

Efficacy Snapshot

• 50% Objective Response Rate (ORR): Demonstrated among the first six evaluable patients.
• Deep & Durable Responses: Patients experienced responses that improved over time, despite a high baseline disease burden and multiple prior lines of therapy.
• Favorable Safety Profile: Results remained consistent with lifileucel’s performance in other solid tumors.

Addressing a Significant Unmet Medical Need

Iovance Biotherapeutics Inc. highlighted a significant unmet medical need for these aggressive cancers, which currently affect over 8,000 patients annually across the United States and Europe. Current second-line treatment options typically yield objective response rates of less than 5%, with median overall survival often falling severely short, at under one year.

Medical experts involved in the trial noted that this one-time immunotherapy treatment showed unprecedented results for refractory patients who previously relied on chemotherapy with limited efficacy.

Next Steps: Registrational Trial in 2026

The safety profile observed in the study was highly favorable and remained completely consistent with lifileucel’s established performance in other solid tumors like melanoma and lung cancer. Following these overwhelmingly positive early results, Iovance is now planning to launch a single-arm registrational trial specifically targeted for second-line advanced UPS and DDLPS in Q2 2026.

About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company that develops and commercializes pioneering cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally.